Prudence A. Francis

Prudence A. Francis

305 Grattan St
Melbourne, VIC 3000, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 130 publications

Cognitive Behavior vs Bright Light Therapy for Insomnia in Women Undergoing Chemotherapy for Breast Cancer: A Randomized Clinical Trial.

Cognitive Behavior vs Bright Light Therapy for Insomnia in Women Undergoing Chemotherapy for Breast Cancer: A Randomized Clinical Trial.

Journal: JAMA network open

Published: August 27, 2026

Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.

Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: April 16, 2026

Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer.

Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer.

Journal: The New England journal of medicine

Published: January 28, 2026

A Randomized Controlled Trial: Evaluating the Sleep, Cancer and Rest (SleepCaRe) Trial to Improve Health-Related Quality of Life in Women Undergoing Chemotherapy for Breast Cancer.

A Randomized Controlled Trial: Evaluating the Sleep, Cancer and Rest (SleepCaRe) Trial to Improve Health-Related Quality of Life in Women Undergoing Chemotherapy for Breast Cancer.

Journal: Psycho-oncology

Published: November 24, 2025

Identifying premenopausal patients with early-stage hormone receptor-positive breast cancer at minimal risk of distant recurrence by breast cancer index.

Identifying premenopausal patients with early-stage hormone receptor-positive breast cancer at minimal risk of distant recurrence by breast cancer index.

Journal: Breast (Edinburgh, Scotland)

Published: November 21, 2025

Assessment of Adjuvant Endocrine Therapy With Ovarian Function Suppression by Breast Cancer Index.

Assessment of Adjuvant Endocrine Therapy With Ovarian Function Suppression by Breast Cancer Index.

Journal: JAMA network open

Published: November 03, 2025

Baseline tumour burden and prognosis in breast cancer treated with immune checkpoint inhibitors.

Baseline tumour burden and prognosis in breast cancer treated with immune checkpoint inhibitors.

Journal: Breast (Edinburgh, Scotland)

Published: March 19, 2025

Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFT.

Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFT.

Journal: Cancer

Published: March 05, 2025

Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2-Low, Hormone Receptor-Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials.

Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2-Low, Hormone Receptor-Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials.

Journal: JCO precision oncology

Published: January 24, 2025

Supervised Exercise for Patients With Metastatic Breast Cancer: A Cost-Utility Analysis Alongside the PREFERABLE-EFFECT Randomized Controlled Trial.

Supervised Exercise for Patients With Metastatic Breast Cancer: A Cost-Utility Analysis Alongside the PREFERABLE-EFFECT Randomized Controlled Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 13, 2025

Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer.

Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer.

Journal: JAMA oncology

Published: August 15, 2024

Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61-20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial.

Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61-20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial.

Journal: The Lancet. Oncology

Published: July 17, 2024

Showing 1-12 of 130

Last Updated: 09/26/2026